DSG2 and Arrhythmogenic right ventricular dysplasia: In addition, ARVC disease phenotypes in the DSG2 mutant mouse model could also be dampened by NF-κB inhibition via Bay 11-7082 (Chelko et al. 2019), further demonstrating inflammatory modulators as potential therapeutic targets for ARVC.